Literature DB >> 15529258

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.

Xiaodong Zhao1, Fu-Ping Chen, A George Megaw, Wayne M Sullender.   

Abstract

BACKGROUND: Palivizumab (PZ) is the only monoclonal antibody in use against a human infectious disease. PZ is given as prophylaxis against infection with respiratory syncytial virus (RSV). An RSV escape mutant, MP4, has been shown to resist PZ prophylaxis in cotton rats.
METHODS: To further define the potential of RSV to resist prophylaxis, additional PZ-resistant viruses were selected in cell culture and were tested for susceptibility to PZ in cotton rats.
RESULTS: Mutant MS412 had an A-->C mutation at nucleotide position 827 in the F gene, resulting in an amino acid change from Lys to Gln at position 272. Mutant F212 had an A-->T mutation at position 816, leading to an amino acid change from Asn to Ile at position 268. In vitro, F212 had impaired growth kinetics. In cell culture, F212 was partially and MS412 was completely resistant to PZ neutralization. A single prophylactic dose of 15 mg/kg PZ protected cotton rats from infection with F212 but not with MS412.
CONCLUSION: Both in vitro and in vivo, individual RSV PZ escape mutants varied in their susceptibility to PZ. Mutations associated with resistance to PZ did not always result in failure of PZ prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15529258     DOI: 10.1086/425515

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.

Authors:  Qing Zhu; Josie M McAuliffe; Nita K Patel; Frances J Palmer-Hill; Chin-fen Yang; Brandon Liang; Lan Su; Wei Zhu; Leslie Wachter; Susan Wilson; Randall S MacGill; Subramaniam Krishnan; Michael P McCarthy; Genevieve A Losonsky; JoAnn A Suzich
Journal:  J Infect Dis       Date:  2011-01-05       Impact factor: 5.226

2.  Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

Authors:  Jarrod J Mousa; Marion F Sauer; Alexander M Sevy; Jessica A Finn; John T Bates; Gabriela Alvarado; Hannah G King; Leah B Loerinc; Rachel H Fong; Benjamin J Doranz; Bruno E Correia; Oleksandr Kalyuzhniy; Xiaolin Wen; Theodore S Jardetzky; William R Schief; Melanie D Ohi; Jens Meiler; James E Crowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

3.  In vivo selection of respiratory syncytial viruses resistant to palivizumab.

Authors:  Xiaodong Zhao; Wayne M Sullender
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 5.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

6.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Authors:  José A Melero; Martin L Moore
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

7.  Structural basis of respiratory syncytial virus neutralization by motavizumab.

Authors:  Jason S McLellan; Man Chen; Albert Kim; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2010-01-24       Impact factor: 15.369

8.  Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure.

Authors:  Yonatan H Grad; Ruchi Newman; Michael Zody; Xiao Yang; Ryan Murphy; James Qu; Christine M Malboeuf; Joshua Z Levin; Marc Lipsitch; John DeVincenzo
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

9.  Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.

Authors:  John T Bates; Christopher J Keefer; James C Slaughter; Daniel W Kulp; William R Schief; James E Crowe
Journal:  Virology       Date:  2014-03-03       Impact factor: 3.616

10.  Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.

Authors:  Asunción Mejías; Octavio Ramilo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.